Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 11Neoplasm Metastasis 3Lung Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Thymoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Gastroesophageal Cancer 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Clinical Stage IVB Gastric Cancer AJCC v8 1Clinical Stage III Gastric Cancer AJCC v8 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Brain Neoplasms 1

Interventions

irinotecan sucrosofate 1Ramucirumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Unresectable Gastric Adenocarcinoma × Ramucirumab × Clear all
NCT03739801 2020-03-27

MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

University of Southern California

Phase 1/2 Withdrawn
Gastrointestinal

Locally Advanced Unresectable Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡